Clinical toxicology of newer recreational drugs

Clinical Toxicology

Volumn 49, Issue 8, 2011, Pages 705-719

  Hill, Simon L ^a,b   Thomas, Simon H L ^a,b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Designer drug; Entactogen; Hallucination; Phenethylamine; Piperazine; Piperidine; Research chemical; Stimulant; Tryptamine

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 4' METHYLMETHCATHINONE; 5 METHOXY ALPHA METHYLTRYPTAMINE; ALPHA METHYLTRYPTAMINE; AMPHETAMINE DERIVATIVE; BROLAMFETAMINE; CATHINONE; CENTRAL STIMULANT AGENT; DESOXYPIPRADROL; DIBENZOFURAN DERIVATIVE; DIPHENYLPROLINOL; DOPAMINE; ETHYLTRYPTAMINE; INDAN DERIVATIVE; MONOAMINE; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; N,N DIMETHYLTRYPTAMINE; NAPHYRONE; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PSYCHEDELIC AGENT; RECREATIONAL DRUG; SEROTONIN; TOXIDROME; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; CENTRAL NERVOUS SYSTEM; CONCEPTUAL FRAMEWORK; DOPAMINE UPTAKE; DRUG ABUSE; DRUG MECHANISM; DRUG STRUCTURE; EPIDEMIOLOGICAL DATA; HUMAN; MEDICOLEGAL ASPECT; MEDLINE; NEUROTOXICITY; NONHUMAN; PUBLICATION; REVIEW; SEROTONIN RELEASE;

ANIMALS; CLINICAL MEDICINE; DESIGNER DRUGS; HUMANS; MOLECULAR STRUCTURE; NEUROTOXICITY SYNDROMES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053917044     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2011.615318     Document Type: Review

References (169)

1. European Monitoring Centre for Drugs and Drug Addiction. 2009 Annual report on the state of the drugs problem in Europe. Available at http://www.emcdda.europa.eu/publications/annual-report/2009
2. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health. Available at http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8results.cfm
3. Measham F, Moore K. Repertoires of Distinction: Exploring patterns of weekend polydrug use within local leisure scenes across the English night time economy. Criminol Criminal Justice 2009; 9:437-464.
4. Hoare R, Flatley J. Drug misuse declared: Fi ndings from the 2007 /08 British Crime Survey, Home Offi ce Statistical Bulletin 2008, Home Offi ce, London. Accessed at http://tonydagostino. co.uk/tony-dagostin-1./Resources-fi les/hosb1209.pdf.
5. Clatts MC, Goldsamt LA, Yi H. Club drug use among young men who have sex with men in NYC: A preliminary epidemiological profi le. Subst Use Misuse 2005; 40:1317-1330. Accessed at http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2735842/.
6. Hickson F, Bonell C, Weatherburn P, Reid D. Illicit drug use among men who have sex with men in England and Wales. Addict Res Theory 2010; 18:14-22.
7. Measham F, Moore K, Newcombe R, Welch Z. Tweaking, bombing, dabbing and stockpiling: The emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 2010; 10:14-21.
8. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depen doi:10.1016/j.drugalcdep. 2011.02.011.
9. Davey Z, Corazza O, Schifano F, Deluca P. Mass-information: Mephedrone, myths and the new generation of legal highs. Drugs Alcohol Today 2010; 10:24-28.
10. International Narcotics Control Board Statement. Available at http:// www.incb.org/pdf/e/press/2001/press-release-2001-02-14-1.pdf.
11. Davies S, Wood DM, Smith G, Button J, Ramsey J, Archer R, et al. Purchasing ' legal highs ' on the Internet-is there consistency in what you get? Q J Med 2010; 103:489-493.
12. Brandt SD, Sumnall HR, Measham F, Cole J. The confusing case of NRG-1. BMJ 2010; 341:3564.
13. http://www.emcdda.europa.eu/publications/drug-profi les/ syntheticcannabinoids.
14. http://www.emcdda.europa.eu/attachements.cfm/att-33346-EN-Risk4.pdf.
15. http://www.emcdda.europa.eu/publications/drug-profi les/syntheticcocaine- derivatives.
16. James D, Adams RD, Spears R, Cooper G, Lupton DJ, Thompson JP, Thomas SHL. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2010; published online August 25, 2010. Accessed at http://emj. bmj.com/content/early/2010/08/25/emj.2010.096636. full.
17. Wood DM, Conran P, Dargan PI. ICD-10 coding: Poor identifi cation of recreational drug presentations to a large emergency department. Emerg Med J 2011; 28:387-389. Epub 2010.
18. Schmidt MM, Sharma A, Schifano F, Feinmann C. Legal highs on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int 2011; 206:92-97.
19. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Research Report: Mephedrone, new kid for the chop? Addiction 2011; 106:154-161.
20. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. Q J Med 2010; 103:875-879.
21. Nichols DE. Hallucinogens. Pharmacol Therapeut 2004; 101: 131-181.
22. Nagai F, Nonaka R, Satoh K, Kamimura H. The effects of non medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007; 559:132-137. (Pubitemid 46295399)
23. Ray TS. Psychedelics and the Human Receptorome. PLOS ONE 2010; 5:e9019.
24. European Monitoring Centre for Drugs and Drug Addiction 2007. Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances. Available at http://www. emcdda.europa.eu/publications/ risk-assessments/bzp.
25. Advisory Council on the Misuse of Drugs 2008. Control of 1-benzylpiperazine and related compounds. Available at http://www. homeoffi ce.gov.uk/publications/drugs/acmd1/ACMD-BZP-Report.
26. Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/ trifl uoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 2008; 31:1-7.
27. Campbell H, Cline W, Evans M, Lloyd J, Peck AW. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former Addicts. Eur J Clin Pharmacol 1973; 6:170-176.
28. Lin JC, Jan RK, Kydd RR, Russell BR Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. Drug Test Anal 2011 Apr 28. doi: 10.1002/dta.285.
29. Baumann MH, Clark RD, Budzynski AG, Patilla JS, Blough BE, Rothman RB. Effects of ' ' Legal X ' ' piperazines analogs on dopamine and serotonin release in rat brain. Ann NY Acad Sci 2004; 1025: 189-197. (Pubitemid 39643862)
30. Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of ' party pill ' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 2009; 186:63-67.
31. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Metabolism and the urinary excretion profi le of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol 2006; 30:38-43. (Pubitemid 44270341)
32. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, Jones AL. Collapse, reported seizure-and an unexpected pill. Lancet 2007; 369:1490. (Pubitemid 46635785)
33. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and discriminating stimulus effects of 1-benzylpiperazine and trifl uoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 2005; 77:161-168. (Pubitemid 40128194)
34. Wikströ m M, Holmgren P, Ahlner J. A2 (N -benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004; 28:67-70. (Pubitemid 38112321)
35. Schep LJ, Slaughter RJ, Vale JA, Beasley DMG, Gee P. Review: The clinical toxicology of the designer ' ' party pills ' ' benzylpiperazine and trifl uoromethylphenylpiperazine. Clin Toxicol 2011; 49:131-141.
36. Austin H, Monasterio E. Acute psychosis following ingestion of ' Rapture ' Australas Psychiatry 2004; 12:406-408. (Pubitemid 40103734)
37. Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. N Z Med J 2005; 118:U1784.
38. Gee P, Jerram T, Bowie D. 2010. Multiorgan failure from 1- benzylpiperazine ingestion-legal high or lethal high? Clin Toxicol 2010; 48:230-233.
39. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Fatal brain edema after ingestion of ecstasy and benzylpiperazine. Dtsch Med Wochenschr 2001; 126:809-811. (Pubitemid 32661843)
40. Elliott S, Smith C. Investigation of the fi rst deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008; 32:172-177. (Pubitemid 351362752)
41. Chiang WK. Amphetamines. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland M, Lewin NA, Nelson LS, eds. Goldfrank ' s Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011:1078-1090.
42. Europol-European Monitoring Centre for Drugs and Drug Addiction joint report on a new psychoactive substance: 1-(3-chlorophenyl) piperazine [mCPP]. 2005. Available at http://www.emcdda.europa. eu/attachements.cfm/att-33257-EN- Annex-1-mCPP-Technical-Information.pdf
43. Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: A comparison with d-amphetamine and mCPP, Drug Alcohol Depend 2003; 72:33-44. (Pubitemid 37255328)
44. Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR. Determining the subjective effects of TFMPP in human males Psychopharmacol 2010; 211:347-353.
45. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-Substituted piperazines abused by humans mimic the molecular mechanism of 3,4-Methylenedioxymethamphetamine (MDMA, or ' Ecstasy ' ). Neuropsychopharmacol 2005; 30:550-560. (Pubitemid 40271157)
46. Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, Rao ML. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: Implication for the pharmacodynamic profi le. Pharmacopsychiatry 2004; 37:180-188. (Pubitemid 38916428)
47. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifl uoromethylphenyl) piperazine (TFMPP): Gas chromatography/ mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and phase II metabolism and on its toxicological detection in rat urine. J Mass Spectrom 2003; 38:971-981. (Pubitemid 37121814)
48. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3- chlorophenyl)piperazine (mCPP): GC-MS Studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol 2003; 27:560-568. (Pubitemid 37500377)
49. Erowid accessed at http://www.erowid.org/chemicals/tfmpp/tfmpp-article1. shtml.
50. Klaassen T, Ho Pian LK, Westenberg HG, den Boer JA, van Praag HM. Serotonin syndrome after challenge with the 5-HT agonist metachlorophenylpiperazine. Psychiatry Res 1998; 79:207-212. (Pubitemid 28346468)
51. Wood DM, Button J, Liddler S, Ramsey J, Holt DW, Dargan PI. Dissociative and sympthomimetic toxicity associated with recreational use of 1-(3-trifl uoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperazine (BZP). J Med Tox 2008; 4:254-257.
52. Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N, et al. Randomised double-blind, placebo-controlled trial of the effects of the ' party pills ' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010; 24:1299-1308.
53. Leysen JE, Janssen PF, Niemegeers CJ. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment. Eur J Pharmacol 1989; 163:145-149. (Pubitemid 19107556)
54. Winstock A, Mitcheson L, Ramsey J, Marsden J. Mephedrone: Use, subjective effects and health risks. Short title: Mephedrone and health risks. ' Postprint ' ; doi:10.1111/j.1360-0443.2011.03502.x
55. Nichols DE. Medicinal chemistry and structure activity relationships. In: Cho AK, Segal DS, ed. Amphetamine and Its Analogs. Psychopharmacology, Toxicology and Abuse. San Diego, CA: Academic Press Inc.; 1994:3-33.
56. Villalobos CA, Bull P, Saez P, et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Brit J Pharmacol 2004; 141:1167-1174. (Pubitemid 38582254)
57. Acuna-Castillo C, Villalobos C, Moya PR, Saez P, Cassels BK, Huidobro-Toro JP. Differences in potency and effi cacy of a series of phenylisopropylamine/phenethylamine pairs at 5-HT2a and 5-HT2c receptors. Brit J Pharmacol 2002; 136:510-519. (Pubitemid 34717695)
58. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006; 70:1956-1964. (Pubitemid 44771911)
59. Rusterholz DB, Spratt JL, Long JP, Kelly TF. Serotonergic and dopaminergic involvement in the mechanism of action of R-(-)-2, 5-dimethoxy- 4-bromoamphetamine (DOB) in cats. Life Sci 1978;1499-1506. (Pubitemid 9095800)
60. http://www.erowid.org/chemicals/dob/dob-effects.shtml.
61. Cheng HC, Long JP, Nichols DE, Barfknecht CF. Effects of psychotomimetics on vasculare strips: Studies of methoxylated amphetamines and optical isomers of 2,5-dimethoxy-4-methylamphetamine and 2,5-dimethoxy-4-bromoamphetamine. PET 1974; 188:114-123.
62. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromamphetamine) overdose. Forensic Sci Int 2005; 153:85-91. (Pubitemid 41008658)
63. Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983; 249:1477-1479. (Pubitemid 13158582)
64. Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 1998; 41:5148-5149. (Pubitemid 29016308)
65. Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecifi c synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists. J Med Chem 2001; 44:1003-1010. (Pubitemid 32861624)
66. Psychonaut WebMapping Research Group. 2009. Bromo- Dragonfl y report. Institute of psychiatry, King ' s College London, London UK. Available at http://194.83.136.209/documents/reports/ Bromodragonfl y.pdf.
67. Andreasen MF, Telving R, Birkler R, et al. A fatal poisoning involving Bromo-Dragonfl y. Ann Toxicol Anal 2008; 20(S1):1-55.
68. Personne M, Hulten P. Bromo-Dragonfl y, a life threatening designer drug. Clin Toxicol 2008; 46:379.
69. Wood DM, Looker JJ, Shaikh L, Button J, Puchnarewicz M, Davies S, et al. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol 2009; 5:226.
70. Erowid.org accessed at http://www.erowid.org/chemicals/2cb-fl y/2cb-fl y-info1.shtml.
71. Erowid.org accessed at http://www.erowid.org/chemicals/2cb-fl y/2cb-fl y-death1.shtml (on October 6, 2010
72. Ling LH, Marchant C, Buckley NA, Prior M, Irvine RJ. Poisoning with the recreational drug paramethoxyamphetamine ( ' death ' ). Med J Australia 2001; 174:453-455. (Pubitemid 32466069)
73. De Letter EA, Coopman VAE, Cordonnier JACM, Piette MHA. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: Clinico-pathological fi ndings. Int J Legal Med 2001; 114:352-356. (Pubitemid 32691860)
74. Elliot SP. Fatal poisoning with a new phenethylamine: 4-methylthioamphetamine (4-MTA). J Anal Toxicol 2000; 24:85-89.
75. Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. Recent paramethoxyamphetamine deaths. J Anal Toxicol 1998; 22:169-172. (Pubitemid 28128966)
76. Lamberth PG, Ding GK, Nurmi LA. Fatal paramethoxy-amphetamine (PMA) poisoning in the Australian Capital Territory. Med J Australia 2008; 188:426.
77. Carmo H, Brulport M, Hermes M, et al. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 2007; 229:236-244. (Pubitemid 44937495)
78. Europol- EMCDDA Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). 2010. Available at http://www.emcdda.europa. eu/attachements.cfm/att-102496-EN-Europol-EMCDDA-Joint-Report-Mephedrone.pdf.
79. EMCDDA. Appendix 2 to Annex 1 (Technical report on mephedrone): Mephedrone: Additional studies overview of prevalence, use patterns, effects. Accessed at http://www.ofdt.fr/BDD/publications/ docs/rarOEDTmephA1A2.pdf.
80. Brunt TM, Poortman A, Niesink RJM, van den Brink W. Instability of the ecstasy market and a new kid on the block: Mephedrone. J Psychopharmacol (Online First), published on September 8, 2010. doi:10.1177/0269881110378370.
81. Australian institute of criminology. Patterns of mephedrone, GHB, Ketamine and Rohypnol use among police detainees. Accessed at http://www.aic.gov.au/publications/current%20series/rip/1-10/ 16.aspx.
82. Lea T, Reynolds R, De Wit J. Mephedrone use among same-sex attracted young people in Sydney, Australia. Drug Alcohol Rev, March 31, 2011. doi: 10.1111/j.1465-3362.2011.00288.x.
83. US department of justice, Drug enforcement agency. Microgram bulletin, April 2011. Accessed at http://www.justice.gov/dea/ programs/forensicsci/ microgram/mg2011/mg0411.pdf.
84. UK Home offi ce. Available at http://www.homeoffi ce.gov.uk/ about-us/home-offi ce-circulars/circulars-2010/010-2010/.
85. http://www.erowid.org/chemicals/4-methylmethcathinone/ 4-methylmethcathinone-law.shtml.
86. Thomas SHL, James DA, Spears R, Cooper G, Wood K, Dyas J, et al. Effects of legal control on enquiries to the UK National Poisons Information Service relating to recreational cathinone use. Clin Toxicol 2011; 49:214.
87. Winstock A, Mitcheson L, Marsden J. Mephedrone: Still available and twice the price. Lancet 2010; 376:1537.
88. McElrath K, O' Neill C. Experiences with mephedrone pre- and post-legislative controls: Perceptions of safety and sources of supply. Int J Drug Policy, 2011. doi:10.1016/j.drugpo.2010.11.001.
89. Gibbons S, Zloh M. An analysis of the ' legal high ' mephedrone. Bioorg Med Chem Lett 2010; 20:4135-4139.
90. de Bie RMA, Gladstone RM, Strafella AP, Ko JH, Lang AE. Manganese-induced parkinsonism associated with methcathinone (Ephedrone) abuse. Arch Neurol 2007; 64:886-889. (Pubitemid 46919845)
91. Sikk K, Haldre S, Aquilonius SM, Taba P. Manganese-induced parkinsonism due to Ephedrone abuse. Parkinsons Disease 2011, published online. Accessed at http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3043321/?tool-pubmed
92. Meyer MR, Peters FT, Maurer HH. Metabolism of the new designer drug mephedrone and toxicological detection of the beta keto designer drugs mephedrone, butylone and methylone in urine. Ann Toxicol Anal 2009; 21(S1)Abstracts:22-23.
93. Cozzi NV, Sievert MK, Shulgin AT, Jacob P, Ruoho AE. Inhibition of plasma membrane monoamine transporters by ǎ -ketoamphetamines. Eur J Pharmacol 1999; 381:63-69. (Pubitemid 29488590)
94. Rudnick G, Wall SC. The molecular mechanism of ' e cstasy ' [3,4- methylenedioxymethamphetamine(MDMA)]: Serotonin transporters are targets for MDMA induced serotonin release. Proc Natl Acad Sci USA 1992; 89:1817-1821.
95. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI. Case series of individuals with analytically confi rmed acute mephedrone toxicity. Clin Toxicol 2010; 48:924-927.
96. Regan L, Mitchelson M, Macdonald C. Mephedrone toxicity in a Scottish emergency department. Emerg Med J 2010. doi:10.1136/ emj.2010.103093.
97. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2011; 28:280-282.
98. Dickson AJ, Vorce SP, Levine B, Past MR. Case report: Multiple-drug toxicity caused by the coadministration of 4-Methylmethcathinone (Mephedrone) and Heroin. J Anal Toxicol 2010; 34:162-168.
99. Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, et al. Recreational use of mephedrone (4-Methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010; 6:327-330.
100. Gustaffsson D, Escher C. Mefedron. Internetdrog som tycks ha kommit f ö r att stanna. (Mephedrone-Internet drug that seems to have come to stay). L ä kartidningen 2009; 106:2769-2771.
101. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int 2011; 20:206(1-3):e93-e95.
102. Emergency department visits after use of a drug sold as 'b ath salts'-Michigan, November 13, 2010 to March 31, 2011. Centers for Disease Control and Prevention (CDC).MMWR Morb Mortal Wkly Rep 2011 May 20; 60(19):624-627.
103. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 2011; 35:188-191.
104. Nicholson PJ, Quinn MJ, Dodd JD. Headshop heartache: Acute mephedrone ' meow ' myocarditis. Heart 2010; 96:2051-2052.
105. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O'Riordan JI. A harmless high? Lancet 2010; 376:742.
106. Ghodse AH, Corkery J, Oyefeso A, Schifano F, Ahmed K, Naidoo V. Drug related deaths in the UK. Annual report 2010. International Centre for Drug Policy, St George ' s, University of London, UK.
107. Becker J, Neis P, Rö hrich J, Zö rntlein S. A fatal paramethoxymethamphetamine intoxication. Leg Med (Tokyo) 2003; 5:S138-S141. (Pubitemid 36537851)
108. Wilkstrom M, Thelander G, Nystrom I, Kronstrand R. Two fatal intoxications with the new designer drug Methedrone (4-Methoxymethcathinone). J Anal Toxicol 2010; 34:594-598.
109. Archer RP. Fluoromethcathinone, a new substance of abuse. Forensic Sci Int 2009; 185:10-20.
110. Springer D, Fritschi G, Maurer HM. Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4 ́ -methyl- á pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B 2003; 796:253-266. (Pubitemid 37329670)
111. Meltzer PC, Butler D, Deschamps JR, Madras BK. 1-(4-methylphenyl)-2- pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 2006; 49:1420-1432. (Pubitemid 43271895)
112. http://www.erowid.org/experiences/exp.php?ID-85168.
113. Advisory Council on the Misuse of Drugs. Consideration of the cathinones. Available at http://www.homeoffi ce.gov.uk/publications/ drugs/acmd1/acmd- cathinodes-report-2010?view-Binary.
114. UK Home Offi ce. Available at http://www.homeoffi ce.gov.uk/drugs/ drug-law/naphyrone/.
115. http://www.erowid.org/library/books-online/pihkal/pihkal020. shtml.
116. Carmo H, Hengstler JG, de Boer D, Ringel M, Remiã o F, Carvalho F, et al. Metabolic pathways of 4-bromo-2,5- dimethoxyphenethylamine (2C-B): Analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 2005; 206:75-89. (Pubitemid 39610478)
117. R ohanova M, Pá l ení c ?e k T, Balí k ová M. Disposition of 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2 -hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol Lett 2008; 178:29-36.
118. Páleníĉek T, Rohanová M, Balí ková M, Horáĉek J. Behavioral Effects of 2C-B in Rats-study on prepulse inhibition of acoustic startle and locomotion-a preliminary report. Presented in poster form at ICADTS 2007. Available at http://www.icadts2007.org/ print/poster14-psychedelic2cb.pdf.
119. Huang HH, Bai YM. Persistent psychosis after ingestion of a single tablet of ' 2C-B ' Prog Neuro-Psychopharmacol Biol Psychiat 2010. doi:10.1016/j.pnpbp. 2010.10.018.
120. Miyajima M, Matsumoto T, Ito S. 2C-T-4 intoxication: Acute psychosis caused by a designer drug. Psychiatr Clin Neurosci 2008; 62:243. (Pubitemid 351537718)
121. Curtis B, Kemp P, Harty L, Choi C, Christensen D. Postmortem identifi cation and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 2003; 27:493-498. (Pubitemid 37185861)
122. Ambrose JB, Bennett HD, Lee HS, Josephson SA. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 2010; 16:199-202.
123. Oberlender R, Nichols DE. Structural variation and (+)-amphetaminelike discriminative stimulus properties. Pharmacol Biochem Behav 1991; 38:581-586.
124. McDermed JD, McKenzie GM, Phillips AP. Synthesis and Pharmacology of some 2-aminotetralins. Dopamine Receptor Agonists. J Med Chem 1975; 18:362-367.
125. E rowid. Available at http://www.erowid.org/chemicals/2-aminoindan/ 2-aminoindan.shtml.
126. Kalant H. The pharmacology and toxicology of ' e cstasy' (MDMA) and related drugs. CMAJ 2001; 65:917-928. (Pubitemid 34028233)
127. Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy) amphetamine (MDA). J Med Chem 1990; 33:703-710. (Pubitemid 20047595)
128. Nichols DE, Johnson MP, Oberlender R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol Biochem 1991; 38:135-139.
129. Kamata HT, Shima N, Zaitsu K, Kamata T, Miki A, Nishikawa M, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006; 36:709-723. (Pubitemid 44195985)
130. Sogawa C, Sogawa N, Ohyama K, Kikura-Hanajiri R, Goda Y, Sora I, Kitayama S. Methylone and monoamine transporters: Correlation with toxicity. Curr Neuropharmacol 2011; 9:58-62.
131. Dal Cason TA, Young R, Glennon RA. Cathinone: An investigation of several N-alkyl and Methylenedioxy-substituted analogs. Pharmacol Biochem 1997; 58:1109-1116. (Pubitemid 28108223)
132. http://www.erowid.org/chemicals/methylone/methylone-effects. shtml.
133. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R, et al. Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuro-Psychoph 2007; 31:288-291. (Pubitemid 44959240)
134. Erowid. Available at http://www.erowid.org/chemicals/bk-mbdb/ bk-mbdb.shtml.
135. Psychonaut web mapping research project. MDPV Report. Available at http://www.psychonautproject.eu/documents/reports/MDPV.pdf
136. North Yorkshire Police Force. Accessed on October 18, 2010 at http://www.northyorkshire.police.uk/index.aspx?articleid-4030.
137. Erowid. Available at http://www.erowid.org/chemicals/mdpv.
138. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 3 ' ,4 ' -methylenedioxy-alphapyrrolidinopropiophenone studied in urine using gas chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 793:377-388. (Pubitemid 37271978)
139. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE. Synthesis and pharmacological examination of benzofuran, indan and tetralin analogues of 3,4-methylenedioxyamphetamine. J Med Chem 1993; 36:3700-3706. (Pubitemid 24004369)
140. James DA, Hill S, Holmes P, Spears R, Thomas SHL. Clinical characteristics of 6-(2-Aminopropyl) benzo furan ( ' Benzofury ' ) toxicity reported to the UK National Poisons Information Service (abstract). Clin Tox 2011; 49:215.
141. Fantegrossi WE, Murnane AC, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol 2008; 75:17-33. (Pubitemid 350235393)
142. Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm 2009; 116:1591-1599.
143. Lessin AW, Long RF, Parkes MW. Central stimulant actions of á-alkyl substituted tryptamine in mice. Brit J Pharmacol 1965; 24:49-67.
144. Hoffman A. How LSD originated. J Psychedelic drugs 1979; 11: 53-60.
145. Boland DM, Andollo W, Hime GW, Hearn WL. Fatality due to acute alpha-methyltryptamine intoxication. J Anal Tox 2005; 29:394-398.
146. Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose: A report of eight cases. Western J Med 1974; 120:183-188.
147. Peden NR, Macaulay KEC, Bisset AF, Crooks J, Pelosi AJ. Clinical toxicology of ' magic mushroom ' ingestion. PMJ 1981; 57:543-545. (Pubitemid 11046725)
148. Huang XM, Johnson MP, Nichols DE. Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol 1991; 200:187-190.
149. Erowid. Available at http://www.erowid.org/library/books-online/ tihkal/tihkal06.shtml.
150. Kaplan J, Mandel LR, Stillman R, Walker RW, VandenHeuvel WJA, Gillin JC, Wyatt RJ. Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects. Psychopharmacology 1974; 38:239-245.
151. Szára St. Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism. Cell Mol Life Sci 1956; 12:441-442.
152. Sitaram BR, Lockett L, Talomsin R, Blackman GL, McLeod WR. In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. http://www.sciencedirect.com/sciencê-ob-ArticleURL&-udi- B6T4P-477GR57-2RT&-user-10&-origUdi-B6T4P-477GR57-2RS&-fmt- high&-coverDate-05%2F01%2F1987&-rdoc-1&-orig-article&-origin- article&-zone-related-art&-acct-C000050221&-version-1&- urlVersion-0&-userid-10&md5-fda136688ce2b894bafb442- c879cf237-#Biochem Pharmacol 1997; 36:1509-1512.
153. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. Arch Gen Psychiatry 1994; 51:85-97.
154. Erowid accessed at http://www.erowid.org/library/books-online/tihkal/ tihkal04.shtml.
155. Kamata T, Katagi M, Tsuchihashi H. Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan. Forensic Toxicol 2010; 28:1-8.
156. http://www.erowid.org/library/books-online/tihkal/tihkal18.shtml.
157. http://www.erowid.org/experiences/exp.php?ID-50758.
158. Rogawski MA, Aghajanian GK. Serotonin autoreceptors on dorsal raphe neurons: Structure-activity relationships of tryptamine analogs ' J Neurosci 1981; 1:1148-1154. (Pubitemid 12218107)
159. Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K. Case report: A fatal poisoning with 5-Methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci Int 2006; 163:152-154. (Pubitemid 44442804)
160. Wilson JM, McGeorge F, Smolinske S, Meatherall R. A foxy intoxication. Forensic Sci Int 2005; 148:31-36. (Pubitemid 40029393)
161. Alatrash G, Majhail NS, Pile JC. Rhabdomyolysis after ingestion of ' foxy ' , a hallucinogenic tryptamine derivative. Mayo Clin Proc 2006; 81:550-551.
162. Erowid 5-MeO-AMT vault accessed at http://www.erowid.org/ chemicals/lsd/lsd-media2.shtml.
163. Brush DE, Bird SB, Boyer EW. Monoamine oxidase inhibitor poisoning resulting from internet misinformation on illicit substances. Clin Toxicol 2004; 42:191-195. (Pubitemid 38758532)
164. Herbert JX, Daly F, Tracey JA. Whacked! BMJ letters. Published July 15, 2010. Accessed at http://www.bmj.com/content/341/bmj. c3564.extract/reply (on March 8, 2011
165. UK Government Home Offi ce. Available at http://www.homeoffi ce. gov.uk/media-centre/news/drug-import-ban.
166. Lidder S, Dargan PI, Sexton M, Button J, Ramsey J, Holt DW, Wood DM. Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). J Med Toxicol 2008; 4:167-169.
167. Kaizaki A, Tanaka S, Tsujikawa K, Numazawa S, Yoshida T. Recreational drugs 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-Methylenedioxyamphetamine (MDA), and diphenylprolinol, inhibit neurite outgrowth in PC12 cells. J Toxicol Sci 2010; 35: 375-381.
168. Westphal F, Junge T, Girreser U, Stobbe S, Perez SB. Structure elucidation of a new designer benzylpiperazine: 4-Bromo-2,5 - dimethoxybenzylpiperazine. Forensic Sci Int 2009; 187:87-96.
169. Bluelight. Accessed at http://www.bluelight.ru/vb/archive/index. php/t-303399.html.